Announcements Trials
Browse Landscape

Phase

Phase 1 14Phase NA 5Phase 1/2 3Phase 2 2

Status

Recruiting 202Completed 106Unknown 76Terminated 70Not yet recruiting 54Active not recruiting 47Withdrawn 10Suspended 3Enrolling by invitation 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 13Other hematologic neoplasm 7Lymphoid 6Dermatologic 5Tumor-Agnostic 4Thoracic 4CNS 4Other solid neoplasm 3Myeloid 3Plasma cell 2Genitourinary 2Breast 2Sarcoma 1Gynecologic 1

Conditions

Solid Tumors 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Advanced Solid Tumors 1

Interventions

Sorafenib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Suspended × Other solid neoplasm × Clear all
NCT05416749 2024-11-20

A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 1/2 Suspended
216 enrolled
Other solid neoplasm

Solid Tumors

NCT01627795 2018-04-18

Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment

Oshadi Drug Administration

Phase 1/2 Suspended
17 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma, Neoplasms

NCT01226056 2010-10-21

Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets

Southern Europe New Drug Organization

Phase 1/2 Suspended
45 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡